Intrinsic Value of S&P & Nasdaq Contact Us

Baxter International Inc. BAX NYSE

NYSE • Healthcare • Medical - Instruments & Supplies • US • USD

SharesGrow Score
43/100
2/7 Pass
SharesGrow Intrinsic Value
$25.54
+45.2%
Analyst Price Target
$19.75
+12.3%
SharesGrow 7-Criteria Score All 7 criteria scored · valuation-related highlighted on this page

Baxter International Inc. (BAX) has a negative trailing P/E of -9.2, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 9.2 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -10.88%, forward earnings yield 10.85%. PEG 1.20.

Criteria proven by this page:

  • VALUE (78/100, Pass) — analyst target implies upside (+12.3%).
  • Forward P/E 9.2 — analysts expect a return to profitability with estimated EPS of $1.91 for FY2026.
  • PEG Ratio 1.20 — between 1.0–2.0 indicates moderate valuation relative to growth.
  • Trailing Earnings Yield -10.88% — negative yield confirms the company is currently unprofitable. Investors are paying for a turnaround rather than current earnings. Forward yield improves to 10.85% as earnings recover.
  • Analyst consensus target $19.75 (+12.3% upside) — modest upside expected.

Overall SharesGrow Score: 43/100 with 2/7 criteria passed.

SharesGrow 7-Criteria Score
43/100
SG Score
View full scorecard →
VALUE
78/100
Price-to-Earnings & upside
Proven by this page
~
FUTURE
40/100
Analyst consensus
→ Forecast
PAST
25/100
→ Income
HEALTH
33/100
Debt-to-Equity & liquidity
→ Health
~
MOAT
49/100
→ Income
GROWTH
63/100
→ Income
INCOME
10/100
→ Income

Valuation Snapshot — BAX

Valuation Multiples
P/E (TTM)-9.2
Forward P/E9.2
PEG Ratio1.20
Forward PEG1.20
P/B Ratio1.43
P/S Ratio0.78
EV/EBITDA21.7
Per Share Data
EPS (TTM)$-1.86
Forward EPS (Est.)$1.91
Book Value / Share$11.87
Revenue / Share$21.88
FCF / Share$0.63
Yields & Fair Value
Earnings Yield-10.88%
Forward Earnings Yield10.85%
Dividend Yield2.10%
SharesGrow IV$25.54 (+45.2%)
Analyst Target$19.75 (+12.3%)

Historical Valuation

Year P/E (TTM) PEG Ratio P/B Ratio P/S Ratio Dividend Yield
2016 4.9 0.01 2.92 2.38 1.11%
2017 58.3 -0.66 3.85 3.32 0.90%
2018 22.7 0.13 4.48 3.17 1.07%
2019 42.5 -1.21 5.40 3.75 0.99%
2020 37.1 3.65 4.70 3.50 1.16%
2021 33.6 1.87 4.75 3.55 1.23%
2022 -10.6 0.04 4.40 2.55 2.23%
2023 7.4 -0.04 2.33 1.89 3.00%
2024 -22.9 0.18 2.14 1.40 3.97%
2025 -10.2 -0.27 1.60 0.87 3.55%

EPS: Actual vs Estimates

P/E Ratio & Earnings Yield

Earnings Per Share (EPS) History

Year EPS (Diluted) Revenue Net Income Net Margin
2016 $9.01 $10.16B $4.97B 48.9%
2017 $1.08 $10.58B $602M 5.7%
2018 $2.97 $11.1B $1.55B 13.9%
2019 $1.93 $11.36B $1B 8.8%
2020 $2.13 $11.67B $1.1B 9.4%
2021 $2.53 $12.15B $1.28B 10.6%
2022 $-4.83 $10.06B $-2.43B -24.2%
2023 $5.23 $10.36B $2.66B 25.6%
2024 $-1.27 $10.64B $-649M -6.1%
2025 $-1.75 $11.24B $-957M -8.5%

Analyst Estimates

Year EPS (Avg) EPS Range Revenue (Avg) Revenue Range Analysts
2026 $1.92 $1.85 – $1.95 $11.35B $11.32B – $11.39B 8
2027 $2.01 $1.93 – $2.15 $11.61B $11.31B – $11.79B 9
2028 $2.24 $2.21 – $2.27 $11.98B $11.97B – $11.98B 1
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
Send us a message